Considering the production of circulating PD-L1 was reported to be correlated with stimulation with interferon-γ (25), it is understandable that EGFR-TKI treatment did not decrease sPD-L1 levels like membrane PD-L1 on tumor cells do. This evidence concerns the gene SPDL1 and neoplasm.